EPA Ethyl Ester Composition for Hypertriglyceridemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly hypertriglyceridemia and dyslipidemia, often fail to effectively reduce triglyceride levels and improve lipid profiles, especially in patients who have not responded to existing therapies like Lovaza.
Innovation Solution
A pharmaceutical composition predominantly comprising eicosapentaenoic acid ethyl ester, with minimal or no docosahexaenoic acid, administered orally to provide a high concentration of EPA, which helps in reducing triglyceride levels and improving lipid profiles by increasing HDL-C and reducing LDL-C and Apo B levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies like Lovaza are used to treat hypertriglyceridemia, then cardiovascular disease treatment is provided, but triglyceride levels are not effectively reduced and lipid profiles are not improved
Solution Approach 1:
The patent changes the chemical composition parameters by providing a pharmaceutical composition with at least 96% eicosapentaenoic acid (EPA) by weight, specifically using ethyl eicosapentaenoate, while limiting other fatty acids to no more than 4%. This high-purity EPA composition distinguishes it from existing therapies like Lovaza and achieves superior triglyceride reduction and lipid profile improvement in patients who did not respond to prior treatments.
2Reliability
If a pharmaceutical composition with high EPA concentration is administered, then triglyceride levels are significantly reduced and lipid profiles are improved, but the composition must be highly purified to exclude other fatty acids
Solution Approach 1:
The patent applies extraction by isolating and providing predominantly eicosapentaenoic acid (at least 96% by weight) in the form of ethyl eicosapentaenoate, while removing or limiting other fatty acids to no more than 4% by weight. This extraction of the specific active ingredient from complex fish oil mixtures enables high efficacy in triglyceride reduction while maintaining manufacturing feasibility through targeted purification processes.
3Reliability
If docosahexaenoic acid (DHA) is included in the composition, then omega-3 fatty acid benefits are provided, but the therapeutic effect on triglycerides is reduced compared to EPA-only compositions
Solution Approach 1:
The patent extracts and provides predominantly eicosapentaenoic acid (at least 96% by weight) while specifically limiting docosahexaenoic acid and other fatty acids to no more than 4% by weight. This selective extraction and limitation of DHA content ensures that the composition maintains high therapeutic efficacy for triglyceride reduction, as EPA has been shown to be more effective than DHA for this specific indication.
Data Source
AI summary
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.